We recently had the opportunity to attend the 2025 American Association for Cancer Research (AACR) conference in Chicago. It is one of the largest and most prestigious gatherings in the world for cancer researchers, clinicians, and biotech companies. It was an invaluable experience—an opportunity not only to present our latest findings but also to connect with peers and explore the exciting evolution of oncolytic viral therapies (OVTs). Here’s a recap of the key trends we observed and how they align…

With a lot of countries taking more drastic measures and enforcing limited social contact (known as social distancing), we are left to ask, what is next? We believe it is possible to make a vaccine for COVID-19 that provides long lasting immunity. We also believe we can do this, fast. We recently shared our design here. Since then, we have found several papers that support our line of thinking. Included among these, an article by Liniger et al. that describes…

Let me start by sharing, we are worried about the recent outbreak of COVID-19, also known as SARS-CoV-2 and 2019-nCoV. We feel deeply for all the people who are sick or have loved ones currently infected. We also see the impact on society.  After the initial outbreak, like most of us, we continued with business as usual. We also hoped for and expected the rapid development of vaccines. (Read here about current efforts) At the present moment, however, we feel…

Chad Moles The second in a series of Questions and Answers with the founders of Humane Genomics. Q: Tell me a bit about yourself. I’m a big science nerd. I’ve always been interested in the intersection of science and technology, and how it can advance humanity and healthcare. I also have a soft spot for animals, and have a dog, four cats, and 18 fish.  Q: Why did you decide to become a founder of Humane Genomics? There are several…